Time to relapse in Participants with Stable Response (but not in stable remission) who were randomized in the maintenance phase - Time between participant randomization into the maintenance phase and the first documentation of a relapse event;Change From Baseline in MADRS total score at end of the Maintenance Phase in participants who were randomized in this phase - The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts.Change From Baseline in Subject-reported Depressive Symptoms Using the Patient Health Questionnaire-9 (PHQ-9) Total Score at End of the Maintenance Phase in participants who were randomized in this phase - The PHQ-9 is a 9-item scale used to assess depressive symptoms. Change From Baseline in Clinical Global Impression – Severity (CGI-S) Score at End of Maintenance Phase in participants who were randomized in this phase - The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating. The CGI-S permits a global evaluation of the participant’s condition at a given time. Change From Baseline in Subject-reported Generalized Anxiety Disorder (GAD-7) Score at End of Maintenance Phase in participants who were randomized in this phase - The GAD-7 is a brief and validated measure of overall anxiety.  Item responses are summed to yield a total score with range of 0 to 21, where higher scores indicate more anxiety. Change From Baseline in Subject-reported Healthrelated Quality of Life and Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ- 5D-5L) at End of Maintenance Phase in participants who were randomized in this phase - The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (Level 1 indicating no problem, and Level 5 indicating extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health today.” The descriptive system can be represented as a health state. The EQ-VAS records the respondent’s own assessment of his or her overall health status at the time of completion, on a scale of 0 to 100.; Change From Baseline in Sheehan Disability Scale (SDS) Total Score at End of Maintenance Phase in participants who were randomized in this phase - The SDS is a subject-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability.